Fresenius stock: Deutsche Bank keeps EUR 56.00 target for Fresenius stock

Published on 10/20/2026 at 16:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 6.00 percent to EUR 5.864 billion in Q2 2026. Fresenius stock costs EUR 45.03 on October 20, 2026, up 0.27 percent versus Xetra close.

Deutsche Bank confirms EUR 56.00 target

Deutsche Bank maintained its Buy rating and EUR 56.00 target on October 16, 2026.
Second-quarter revenue reached EUR 5.864 billion, up 6.00 percent year over year.
Fresenius stock costs EUR 45.03 at Lang & Schwarz on October 20, 2026 at 4:13 p.m. CEST, 0.27 percent above the Xetra close of October 19, 2026.
Fresenius will report third-quarter 2026 results on November 4, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) remains covered positively by Deutsche Bank, which maintained its Buy rating and set a EUR 56.00 price target on October 16, 2026, according to Markets Insider. The target is 24.36 percent above the EUR 45.03 price at Lang & Schwarz on October 20, 2026 at 4:13 p.m. CEST, which stood 0.27 percent above the Xetra close of October 19, 2026 at EUR 44.91.

Second-quarter growth supports the case

Fresenius reported second-quarter 2026 revenue of EUR 5.864 billion, an increase of 6.00 percent from EUR 5.571 billion in the second quarter of 2025. The company also reported operating profit of EUR 719 million, up 10.00 percent from EUR 654 million, while core net income rose 14.00 percent to EUR 470 million from EUR 412 million.

Fresenius said the figures exclude special items and that the organic revenue growth measure adjusts for accounting effects linked to hyperinflation in Argentina. Fresenius Kabi generated EUR 2.244 billion in second-quarter revenue, up 7.00 percent, while Helios revenue rose 5.00 percent to EUR 3.526 billion.

Stock stays below its yearly high

At EUR 45.03, the stock was 14.96 percent below its 52-week high of EUR 52.96 and 28.25 percent above its 52-week low of EUR 35.11 on October 20, 2026. Trading volume was 185,071 shares at the latest finance-market snapshot, while the primary Xetra quote stood at EUR 44.99 at 4:15 p.m. CEST.

Valuation and the next date

Markets Insider reported a price-to-earnings ratio of 15.95 and a EUR 56.00 target in its October 16, 2026 report. Fresenius is scheduled to publish third-quarter 2026 results on November 4, 2026, according to the company's investor-relations page. The date gives investors a defined checkpoint for testing whether the second-quarter improvement is continuing.

Comparison with peers

Fresenius: up 0.27 percent, price-to-earnings ratio 15.95, market capitalization EUR 25.3 billion. Fresenius Medical Care (Xetra, EUR): up 0.92 percent, price-to-earnings ratio 11.93, market capitalization EUR 10.5 billion. Siemens Healthineers (Xetra, EUR): up 1.12 percent, price-to-earnings ratio 20.96, market capitalization EUR 46.4 billion.

Target remains the key market marker

Deutsche Bank's EUR 56.00 target places the analyst's valuation 24.36 percent above the Lang & Schwarz price. The next material test is the third-quarter report, where revenue, operating profit and cash generation will show whether the improved earnings quality is translating into sustained performance.

The stock was trading at EUR 45.03 at Lang & Schwarz on October 20, 2026 at 4:13 p.m. CEST, 0.27 percent above the Xetra close of October 19, 2026 at EUR 44.91. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.